Research graph
References from Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Hepatocellular Carcinoma
10.1056/nejmra1713263 · 2019 · External reference
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21492 · 2018 · External reference
Molecular therapies and precision medicine for hepatocellular carcinoma
10.1038/s41571-018-0073-4 · 2018 · External reference
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond
10.2217/fon.15.161 · 2015 · External reference
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
10.1016/j.jhep.2017.09.016 · 2018 · External reference
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
10.1016/j.canlet.2015.06.019 · 2015 · External reference
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(16)32453-9 · 2017 · External reference
Swiss Group for Clinical Cancer, R. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
10.1093/annonc/mdw054 · 2016 · External reference
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial
10.1001/jamaoncol.2019.2792 · 2019 · External reference
Adjuvant therapy for hepatocellular carcinoma: current situation and prospect
10.5582/ddt.2013.v7.4.137 · 2013 · External reference
Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma
10.1186/s12964-019-0430-7 · 2019 · External reference
Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation
10.3892/ol.2018.8640 · 2018 · External reference
Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition
10.3892/ol.2017.6059 · 2017 · External reference
Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma
10.1016/j.bbrc.2019.08.115 · 2019 · External reference
Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action
10.2147/dmso.s181572 · 2018 · External reference
Anti-inflammatory and immunosuppressive properties of the bis-benzylisoquinolines: in vitro comparisons of tetrandrine and berbamine
10.1016/0192-0561(89)90086-6 · 1989 · External reference
Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-gamma in experimental autoimmune encephalomyelitis
10.4049/jimmunol.181.2.1491 · 2008 · External reference
Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia
10.1007/s12185-011-0887-7 · 2011 · External reference
Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca(2)(+)/calmodulin-dependent protein kinase II
10.1158/1535-7163.mct-13-0314 · 2013 · External reference
Berbamine induces SMMC-7721 cell apoptosis via upregulating p53, downregulating survivin expression and activating mitochondria signaling pathway
2018 · External reference
Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice
10.1080/10286020802675076 · 2009 · External reference
Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-beta/Smad signaling
10.1002/ar.22897 · 2014 · External reference
Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action
10.1186/1476-4598-8-81 · 2009 · External reference
Berbamine Enhances the Efficacy of Gefitinib by Suppressing STAT3 Signaling in Pancreatic Cancer Cells
10.2147/ott.s223242 · 2019 · External reference
Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma
10.1016/j.bbcan.2012.10.002 · 2013 · External reference
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
10.1016/j.ccr.2014.05.019 · 2014 · External reference
Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death
10.7150/ijbs.22220 · 2018 · External reference
Epidemiology and Management of Hepatocellular Carcinoma
10.1053/j.gastro.2018.08.065 · 2019 · External reference
New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies
10.1016/j.bbcan.2017.10.002 · 2017 · External reference
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis
10.4161/auto.7.10.16818 · 2011 · External reference
BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway
2019 · External reference
New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
10.2174/1381612821666151002113546 · 2015 · External reference
Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib
10.3892/or.2018.6552 · 2018 · External reference
Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors
10.1016/j.bbcan.2013.12.005 · 2014 · External reference
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy
10.3748/wjg.v20.i41.15269 · 2014 · External reference
Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
10.1016/j.ejmech.2012.07.023 · 2012 · External reference
Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication
10.3389/fonc.2019.00048 · 2019 · External reference
beta-Caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase
10.1002/mc.22035 · 2014 · External reference
Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases
10.1016/j.canlet.2013.12.008 · 2014 · External reference
Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo
10.1074/jbc.m114.601104 · 2014 · External reference
Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel
10.18632/oncotarget.3443 · 2015 · External reference
Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK
10.3892/ijmm.2018.3807 · 2018 · External reference
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT
10.1016/j.ejphar.2018.05.027 · 2018 · External reference
